News

People with ANCA-associated vasculitis (AAV) are at an increased risk of experiencing cardiovascular problems, such as a stroke, according to a new study done in South Korea. Indeed, AAV patients were found to have a more than two times higher risk of cardiovascular health problems than individuals without any…

Intensive care stays are more likely if oxygen-carrying hemoglobin levels are low at hospital admission in adults with kidney disease caused by ANCA-associated vasculitis (AAV), an analysis of medical records found. Severe kidney injury was the primary reason for intensive care unit (ICU) admission in these patients and associated…

In the year before being diagnosed with ANCA-associated vasculitis (AAV), Medicare beneficiaries had significantly higher use and costs of healthcare than those without AAV, an analysis found. According to researchers, earlier identification of AAV is necessary to provide patients with appropriate care and potentially reduce costs and healthcare use.

A reinforced pneumonia (pneumococcal) vaccination scheme, where one of the two vaccine types available is given at higher doses than usual, appears to be safe and may help people with ANCA-associated vasculitis (AAV) who are on rituximab to build better immunity against pneumococcal disease. These are the findings of…

Two cases of teen boys with ANCA-associated vasculitis (AAV) that caused heart problems — a very rare manifestation of the autoimmune disease — were described in a recent report. AAV-related heart issues may contribute to serious health concerns such as stroke, so it is important to screen for these…

Nasal Staphylococcus aureus infections don’t appear to influence disease activity in ANCA-associated vasculitis (AAV) patients with ear, nose, and throat involvement, a study suggests. Treatment with antibiotics to clear S. aureus infections didn’t reduce disease activity either. “Our study shows no difference in systemic and local disease activity between…

An 87-year-old man with ANCA-associated vasculitis (AAV), kidney disease and cutaneous squamous cell carcinoma (cSSC) — a type of skin cancer — partially responded to cemiplimab treatment without developing kidney complications or immune-related side effects. However, his response to cemiplimab was delayed as the tumor initially grew,  but regressed…

Half of patients with ANCA-associated vasculitis (AAV) developed a poor long-term outcome — kidney disease, cancer or death — in the years after their diagnosis, according to a recent study in China. Impaired kidney filtration, low blood potassium, older age, and kidney or heart involvement at diagnosis were among…

Vasculitis UK is supporting a team of scientists investigating whether rising levels of inflammation due to aging — a process dubbed inflammageing — may be at the root of ANCA-associated vasculitis (AAV). The charity has awarded a research grant to professors at Trinity College Dublin, in…

Amgen is the new owner of Tavneos (avacopan), an approved ANCA-associated vasculitis (AAV) therapy, following its successful $3.7 billion cash acquisition of ChemoCentryx. “ChemoCentryx enhances Amgen’s leading inflammation and nephrology portfolio and includes Tavneos (avacopan), a first-in-class treatment for severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), an…